print_label | resize_label

IRESSA (gefitinib) as a first-line treatment for EGFR mutation-positive advanced NSCLC

IRESSA is an oral monotherapy treatment which offers superior progression-free survival, better tolerability and quality of life compared with doublet chemotherapy (carboplatin/paclitaxel) as first-line treatment for EGFR mutation-positive advanced NSCLC.

Read More

The IPASS study

IPASS (IRESSA Pan-ASia Study) was an open label, randomised, parallel-group study that assessed the efficacy, safety and tolerability of IRESSA versus doublet chemotherapy (carboplatin/paclitaxel) as 1st line treatment in a clinically selected population of patients from Asia. Read More

Identifying EGFR mutation positive patients

Epidermal growth factor receptor (EGFR) is a protein found in abnormally high levels on the surface of many types of cancer cells, particularly non-small cell lung cancer (NSCLC) cells. A patient‘s EGFR mutation status (positive or negative) can be confirmed via a diagnostic test using a sample of tumour tissue. Read More

In Europe, IRESSA (gefitinib) is indicated for the treatment of adults with locally advanced or metastatic NSCLC (non small cell lung treatment) with activating mutations of EGFR-TK across all lines of therapy. For the latest IRESSA country by country indication information, please view here.